1. Introduction {#sec0005}
===============

Malignant catarrhal fever (MCF) is a dramatic, fatal disease of cattle and other ungulates, including deer, bison and pigs, caused by ruminant gamma-herpesviruses of the genus *Macavirus* including *Alcelaphine herpesvirus 1* (AlHV-1) and *Ovine herpesvirus-2* (OvHV-2) ([@bib0130; @bib0155; @bib0185]). The disease is characterised by fever and inappetence, frequently with ocular and nasal discharge, and is usually fatal. Death can occur within a few days or up to several weeks after the onset of clinical signs. There is no known treatment or licensed vaccine for MCF but a vaccine strategy to protect animals from MCF caused by AlHV-1 has been described recently ([@bib0095; @bib0160]).

AlHV-1 causes MCF mainly in East Africa, following the range of the wildebeest (*Connochaetes taurinus*), the natural host species, which propagates the virus without apparent clinical signs ([@bib0165]). Wildebeest-associated MCF (WA-MCF) is a significant issue for pastoralists in Eastern and Southern Africa, where cattle are moved to avoid contact with grazing or calving wildebeest ([@bib0015; @bib0060]). WA-MCF also has been a problem in zoological collections that contain wildebeest ([@bib0145; @bib0210]). OvHV-2 naturally infects sheep and causes sheep-associated MCF (SA-MCF), which is found worldwide wherever sheep and cattle (or other MCF-susceptible species) are kept together. SA-MCF is a particular problem in North America where bison are highly susceptible to infection ([@bib0025]).

An interesting feature of MCF is that the natural reservoir species for the viruses causing MCF (*e.g.* wildebeest and sheep) do not exhibit any clinical signs of infection, whereas the disease is dramatic and usually fatal in MCF-susceptible species, some of which are phylogenetically closely related to the reservoir hosts. There are excellent animal models of MCF. In particular, rabbits can be infected with AlHV-1 or OvHV-2 and develop MCF that is very similar to that seen in species naturally susceptible to MCF ([@bib0005; @bib0055]). This model of MCF is now widely used in the analysis of MCF pathogenesis, including analysis of recombinant AlHV-1 ([@bib0010; @bib0045; @bib0070; @bib0075; @bib0085; @bib0125; @bib0140]). Analysis of the pathology of MCF induced by AlHV-1 and OvHV-2 suggests an immune-mediated aetiology, with infiltration/proliferation of lymphocytes in multiple tissues ([@bib0005]). Recent studies have suggested that the proliferating cells are T cells and that many of these may be infected ([@bib0085; @bib0150]). Infected large granular lymphocyte (LGL) cell lines that can be propagated in culture from MCF-affected animals have a non-MHC-restricted cytotoxic T cell phenotype similar to lymphokine-activated killer cells and it has been suggested that these cells cause the dramatic pathology seen in MCF ([@bib0010; @bib0175; @bib0195]). The exact aetiology of MCF pathogenesis has yet to be elucidated.

The involvement of virus gene expression in disease progression has been studied mainly in the rabbit model, where different conclusions have been drawn in different studies. Thus, studies of OvHV-2 infection by intra-nasal or intravenous inoculation have demonstrated lytic cycle-associated gene or protein expression in a range of tissues ([@bib0125; @bib0140]), while analysis of lymphoid tissues from rabbits infected intravenously with AlHV-1 has shown a latency-associated gene expression pattern ([@bib0075; @bib0085]). The inability of either virus to produce infectious virus particles in MCF-susceptible species also suggests that the full programme of lytic virus gene expression is not completed in these hosts. Thus the virus may be limited to some form of latency or to an aberrant pattern of gene expression that is abortive for virus propagation. Analysis of LGL from cattle and rabbits infected with OvHV-2 showed that these cells contained circular (latent) genomes and did not express known lytic cycle transcripts, although some viral gene expression was detected ([@bib0200]). The conflicting evidence of recent studies may also suggest that virus gene expression patterns can vary depending on host species and cell type infected.

Virus-specific and bovine genome microarrays have been used recently to identify virus and host genes whose expression was altered in lymph node tissue of two cattle naturally infected with OvHV-2 ([@bib0135]). This study found that virus infected cells in MCF-affected cattle had a latent pattern of gene expression; that cytotoxicity and cell-cycle associated genes were up-regulated; and notably that IL-2 expression was reduced by about 7-fold on average. Other work has suggested the involvement of IL-15 in the proliferation and cytotoxic activity of infected cells in AlHV-1 induced MCF ([@bib0010]) but the crucial factors in MCF pathogenesis have yet to be confirmed *in vivo*.

Recent work in this laboratory has led to the development of an intranasal route for infection of cattle with AlHV-1 that produces reliable induction of MCF. This has been used in the development of a protective vaccine strategy for MCF in cattle ([@bib0095; @bib0160]) and has provided tissues for detailed analysis of MCF pathology (J. Benavides, H. Todd, G.C. Russell, D.M. Haig, unpublished data). In this paper we describe the use of lymphoid and non-lymphoid tissues from this natural infection of MCF to characterise patterns of gene expression involved in disease pathogenesis. Host gene expression changes due to MCF were identified using RNA extracted from kidney and prefemoral lymph node tissue samples from infected and uninfected cattle. The kidney was used as it represents the cellular pathological changes seen in non-lymphoid tissues in MCF-affected animals. Uninfected kidney contains few lymphoid cells, so the infected tissue may reveal MCF-specific effects that are not distinguished in lymphoid tissue, where the background of lymphoid cells not involved directly in MCF may confound transcriptional analysis. Microarray analysis was used to provide data on approximately 23,000 genes and bioinformatic analysis was used to identify significantly affected genes (up- or down-regulated compared to control samples), functional classes and pathways, shedding light on potential mechanisms of pathogenesis.

This is the first report of gene transcription analysis in a natural disease-susceptible species (cattle) infected with AlHV-1. This should allow any differences and similarities to AlHV-1-infected rabbits or OvHV-2-infected cattle to be revealed.

2. Materials and methods {#sec0010}
========================

2.1. Animals and tissues {#sec0015}
------------------------

The animal experiments were carried out with the approval of the Moredun Research Institute Experiments and Ethical Review Committee and complied fully with the Home Office of Great Britain and Northern Ireland "Animals (Scientific Procedures) Act 1986".

Disease-free and OvHV-2 seronegative male Friesian-Holstein cross calves between 3 and 5 months of age were used. One group of seven cattle was infected intranasally with 10^4.55^ TCID50/ml (50% tissue culture infectious dose) of pathogenic AlHV-1 as described previously ([@bib0095; @bib0160]) while a control group of four animals was left uninfected. The cattle were monitored daily and animals exhibiting a rise in rectal temperature to over 40 °C for at least 2 days with other clinical signs consistent with MCF (inappetence and ocular signs or palpable lymphadenopathy) were euthanised with an overdose of intravenous sodium pentobarbitone. Diagnosis of MCF in these animals was confirmed by gross and histopathological examination of tissue samples and by diagnostic PCR detection ([@bib0205]) of AlHV-1 DNA in blood samples taken at post-mortem. Samples of prefemoral lymph node (LN) and renal cortex (Kid) were collected asceptically from four infected and four control animals and were stored at −20 °C in RNAlater (Life Technologies) as cubes smaller than 5 mm.

2.2. RNA extraction and microarrays {#sec0020}
-----------------------------------

Tissue samples of about 100 mg from control uninfected and MCF affected cattle were used for RNA preparation using Trizol reagent and a silica-based RNA purification system (Qiagen) according to the protocol of ARK-genomics ([www.ark-genomics.org](http://www.ark-genomics.org/)). RNA samples from both tissues of 4 MCF-affected and 4 control animals that passed the RNA quality criteria (*A*~260/280~ ratio = 2.0 ± 0.05; RNA integrity number (RIN) \> 7.0 as assessed using the Eukaryotic RNA 6000 LabChip kit on the Agilent 2100 Bioanalyser) were submitted to ARK-genomics for microarray analysis using Affymetrix GeneChip^®^ Bovine Genome Arrays, representing about 23,000 transcripts.

2.3. Data processing {#sec0025}
--------------------

The data were pre-processed using the MAS 5.0 background adjustment method as outlined in the Affymetrix Statistical Algorithms Description Document (<http://media.affymetrix.com/support/technical/whitepapers/sadd_whitepaper.pdf>). To make measurements from different arrays comparable, data were normalised by the quantile normalisation method ([@bib0040]). Quality assessments of probe-level Affymetrix chip data as well as normalised data were carried out using statistical and graphical methods including MA plots and smoothed histogram plots. The MA-plots showed normalisation was effective; while smoothed histograms indicated there was no systematic bias in the data. The smallest statistically significant difference in mean expression level between affected and control microarrays was about 1.3-fold, demonstrating the reliability of the microarray data presented here. The raw and normalised data from this experiment have been submitted to the ArrayExpress database and have been assigned the accession number E-MEXP-3497.

2.4. Gene expression analysis {#sec0030}
-----------------------------

Gene expression measurements were managed following the MIAME standard ([@bib0050]). A general linear model was fitted to the normalised expression data for differential expression analysis. The coefficients of the fitted models corresponded to two types of RNA sources (tissue type: kidney and lymph node; treatment type: MCF-affected and control). The test statistic for each gene was the moderated *t*-statistic, where the standard error used to calculate the *t*-statistic was estimated using the posterior obtained from an empirical Bayesian model ([@bib0190]). The overall significance of each test was adjusted using the false discovery rate (FDR) approach of [@bib0020]. All analyses were carried out using the Bioconductor suite of programs under the R 2.10.1 environment ([www.r-project.org](http://www.r-project.org/)). Probesets with statistically significant differences in mean expression (FDR-adjusted *p*, *p*~*f*~ \< 0.01 and mean fold-change (FC) \> 2.0) in MCF-affected *versus* control tissues were identified as being suitable for further analysis. These probesets were further analysed using the Ingenuity Pathways Analysis (IPA) system ([www.ingenuity.com](http://www.ingenuity.com/)) and the DAVID online software system ([@bib0100]).

2.5. Real-time quantitative PCR of selected genes {#sec0035}
-------------------------------------------------

Three host genes with significant up-regulation of expression in MCF-affected animals and two genes with no evidence of expression change were selected for real-time PCR confirmation of microarray data. RNA extracted from MCF-affected and control tissues for microarray analysis was also used for these assays to facilitate comparison. The real-time PCR primer and probe sets for each gene were designed using Primer Express software (Applied Biosystems, Warrington, UK) ([Table 1](#tbl0005){ref-type="table"}). Where possible, primer-probe sets were designed to span exons within the respective genes to reduce detection of genomic DNA contamination of RNA. All primers and probes were designed within a narrow annealing temperature range to facilitate the optimisation of the PCR and the simultaneous analysis of multiple genes. Primer and probe optimisation was done according to the instrument manufacturer\'s protocols, using a chequerboard of forward and reverse primer concentrations and titration of probe concentration. Concentrations of primers (900 nM) and probes (250 nM) that gave the lowest threshold cycle (Ct) values and highest fluorescence yield (ΔRn) across a range of concentrations of pooled RNA template were used in all subsequent assays. The real-time quantitative (q)RT-PCR was carried out using the Superscript III platinum One-Step qRT-PCR kit (Life Technologies). Reactions of 20 μl each contained: 10 μl of 2× Reaction Mix; 2.0 μl of each 9 μM primer; 1.0 μl of 5 μM probe; 4.0 μl PCR grade DNase-free water and 1.0 μl (100 ng) total RNA. Prior to analysis, RNA samples were treated with amplification-grade DNAse I (Life Technologies) to reduce background amplification due to genomic DNA contamination. All reactions were carried out on a Roche LightCycler (Roche Applied Science) with the following cycling parameters: 50 °C for 15 min and 95 °C for 2 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s. Data were analysed using LightCycler 480 software (version LCS480 1.5.0.39).

Additionally, parallel control amplifications were performed on each RNA sample in the absence of a reverse transcription step to confirm that genomic DNA contamination did not contribute to the amplification seen.

Bovine ribosomal protein S9 (RPS9) was chosen as the reference gene for these studies because its mean expression was not statistically significantly altered in either tissue in response to MCF in the microarray study. The use of this gene as a gene expression standard has also been validated in multiple cattle tissues under different metabolic conditions ([@bib0030; @bib0115]) and in neoplastic *versus* normal tissues ([@bib0035]).

Analysis of gene expression was performed by relative quantification, normalised to the reference gene RPS9, using the ΔΔCt method as described ([@bib0170]). Briefly, mean Ct values were derived from replicate assays for each gene and sample (tissues: lymph node and kidney; conditions: MCF and control). Next, for each gene, tissue and condition the mean Ct for the RPS9 reference gene was subtracted from the mean Ct for each gene assayed, giving a ΔCt value for that gene/tissue/condition. The ΔCt values for the control group were then subtracted from the respective MCF ΔCt values for each gene and tissue, giving a ΔΔCt value that represented the fold-change between MCF and control animals. Finally, the actual fold-change values between MCF and control samples for each gene and tissue were calculated as 2^−ΔΔCt^.

3. Results {#sec0040}
==========

3.1. Induction of MCF {#sec0045}
---------------------

All animals in the group inoculated intranasally with pathogenic AlHV-1 showed clinical signs of MCF at 27--30 days post-infection. The animals were euthanised on the second or third day of pyrexia, with additional clinical signs consistent with MCF (conjunctivitis or lymphadenopathy). The diagnosis of clinical MCF was confirmed by gross and histopathological findings and by the detection of AlHV-1 virus DNA in blood and tissue samples. Histologically, the kidney from the infected animals showed multifocal interstitial nephritis characterised by non-purulent vasculitis, mainly affecting the arcuate vessels although lesions were also visible in other minor veins and arteries. The lymph node from these animals showed a diffuse follicular lymphoid hyperplasia. Samples from the non-infected animals showed no gross or histological lesions. No clinical signs were seen in the control animals, which were subject to post-mortem examination separately from the MCF-affected animals.

3.2. Identification of differentially expressed genes in MCF-affected tissues {#sec0050}
-----------------------------------------------------------------------------

Analysis of gene expression in two tissues from four animals each in control or MCF-affected groups was done using a single-dye approach on 16 Affymetrix GeneChip Bovine Genome Arrays ([www.affymetrix.com/analysis/index.affx](http://www.affymetrix.com/analysis/index.affx)). RNA for microarray analysis was extracted from tissue samples using a standard protocol and was stored in aliquots at −80 °C. Assessment of RNA integrity by capillary electrophoresis ensured that all RNA used for this analysis was of a similar high quality. The RNA samples submitted for microarray analysis had concentrations between 1.1 and 2.3 mg/ml, *A*~260/280~ ratios of 2.00--2.02 and RIN values of 7.4--8.9. Analysis of hybridisation intensity data after background adjustment and normalisation showed that there was little systematic bias in the observed data.

The array data for each set of four samples was combined and used to identify probesets with statistically significantly different mean expression levels between control and MCF-affected samples within each tissue (*p*-value adjusted for false discovery rate (FDR), *p*~*f*~ \< 0.01). Over 1350 probesets were statistically significantly altered in lymph node while more than 760 were found to be statistically significantly altered in kidney. Of these, 197 probesets in lymph node and 291 probesets in the kidney had average fold-change differences of more than 2. These probesets corresponded to 269 currently annotated genes of which 69 genes were up-regulated by at least 2-fold on average in lymph node compared with 161 genes in the kidney; while 52 genes showed at least 2-fold average down-regulation in the lymph node compared to only 22 genes in the kidney ([supplementary Table S1](#sec0080){ref-type="sec"}). Interestingly, only 35 genes showed altered expression in both tissues ([Table 1](#tbl0005){ref-type="table"}), of which 32 genes were up-regulated. This observation suggests that MCF may induce tissue-specific changes in gene expression.

The observation that most of the genes with altered regulation in both tissues increased in expression during MCF suggests the induction of a core gene set that may be illustrative of the major changes in gene expression that occur in MCF ([Table 2](#tbl0010){ref-type="table"}). Of this group of genes, those with the greatest degree of change included: granulysin (GNLY); granzyme H (GZMH); chemokine (C--X--C motif) ligand 11 (CXCL11); ubiquitin D (UBD); chemokine (C--C motif) ligands 3, 4 and 5 (CCL3, CCL4 and CCL5); the CD8 alpha chain (CD8a); placenta-specific 8 (PLAC8); and indoleamine 2,3-dioxygenase 1 (IDO1). All of these genes have known functions relating to regulation of immune responses and may therefore have roles in the immune dysregulation that characterised MCF.

In contrast, only 3 genes were found to show more than 2-fold reduced expression in both tissues of MCF-affected animals. These genes: cold inducible RNA binding protein (CIRBP); stromal antigen 3 (STAG3); and RNA binding motif protein 3 (RBM3) have known functions related to chromosome pairing (STAG3) and the response to metabolic insults (*e.g.* cold). These differences may be a consequence of MCF, driven either by pathogenic processes or the anti-viral response, but their potential role in disease is unclear. In order to integrate the contributions of multiple genes to MCF pathogenesis and potentially identify biological processes or pathways that may be co-regulated in the diseased tissues, global analysis of up- and down-regulated genes was performed using two systems with distinct approaches.

3.3. Quantitative PCR analysis of gene expression changes {#sec0055}
---------------------------------------------------------

Real-time quantitative (q)PCR was used as an independent assay to verify that the microarray analysis had correctly identified genes with significant expression changes between control and MCF-affected tissues. Five genes were selected for analysis on the basis of microarray data and qPCR primer-probe sets were designed for each gene ([Table 1](#tbl0005){ref-type="table"}). Two genes were selected with the highest expression change in both tissues (GNLY, GZMH; [Table 2](#tbl0010){ref-type="table"}); two genes were selected that had unchanged expression (glucose-6-phosphate isomerise (GPI), RPS9); and one gene was selected that had a high level expression change in one tissue (granzyme B (GZMB); [supplementary Table S1](#sec0080){ref-type="sec"}). No genes with reduced expression were selected for analysis by this method as the expression change in these genes (2--3-fold reduction) was considered to be too low to reliably distinguish by real-time PCR ([Table 2](#tbl0010){ref-type="table"}).

For this analysis RPS9 was selected as the reference gene because it had previously been validated for quantitative analysis in bovine tissues ([@bib0030]) and it exhibited little variation in the microarray analysis (mean fold-change in MCF-affected tissue was 1.03 in kidney and 1.07 in lymph node with *p*~*f*~ values of 0.84 and 0.54 respectively). Quantitative PCR analysis of RPS9 expression in the tissues examined (kidney and lymph node; infected and control) revealed low levels of variation. Ct values for assays of equivalent amounts of total RNA had a standard deviation of less than 1 cycle, supporting the use of RPS9 as a reference gene in this analysis. RNA samples were assayed in duplicate or triplicate and mean Ct values were used to calculate fold-change differences in expression of the selected genes between MCF and control tissues using the ΔΔCt method ([@bib0170]).

These results ([Fig. 1](#fig0005){ref-type="fig"}) verified the up-regulation of GNLY and GZMH, which showed greater than 5-fold increases in mean expression in both tissues, and suggested that expression of GZMB was also increased in both tissues. From the microarray data for the gene GZMB, a statistically significant change in the mean expression level was found in the lymph node (FDR-adjusted probability, *p*~*f*~ = 0.0001). In addition, the *p*~*f*~ value of 0.028 provided weak evidence for an altered mean expression level of GZMB in kidney (fold change of 2.5). Although this did not attain formal statistical significance as defined by the chosen threshold of *p*~*f*~ \< 0.01, it provided some support for the real-time PCR results suggesting that GZMB was up-regulated in both tissues.

The fold-change estimated by real-time PCR for GNLY, GZMB and GZMH was greater than that suggested by the microarray data, especially for the kidney RNA samples. This is in accord with comparative analyses, which observed that fold change results determined by qRT-PCR were greater than those determined by microarray analysis ([@bib0065; @bib0215]). Expression of the housekeeping gene GPI, in contrast to the cytotoxic genes GNLY, GZMH and GZMB, was not affected by MCF, varying by less than 2-fold in either tissue ([Fig. 1](#fig0005){ref-type="fig"}).

These data support the view that the microarray analysis was able to correctly identify significant changes in gene expression due to MCF.

3.4. Analysis of enriched gene ontology terms in differentially expressed genes {#sec0060}
-------------------------------------------------------------------------------

The on-line database system DAVID ([@bib0100; @bib0105]) was used to identify gene ontology terms, functional classes and pathways that were enriched among the differentially expressed genes in each tissue. This analysis is summarised in [Table 3](#tbl0015){ref-type="table"}. DAVID analysis uses only gene identifiers, so separate datasets for up- and down-regulated genes were analysed for each tissue, comprising those genes with *p*~*f*~ \< 0.01 and mean fold-change (FC) greater than 2. Highly enriched annotation terms among up-regulated genes in the kidney included: antigen presentation; inflammatory responses; immune regulation and activation. These processes were also reflected in up-regulated pathways such as antigen presentation, graft rejection and graft-*versus*-host disease, all suggestive of increased immune activity in this tissue ([Table 3](#tbl0015){ref-type="table"}). This contrasts with the enriched terms relating to up-regulated genes in the lymph node (cell division and mitosis in addition to chemokines and autoimmunity) suggesting active immune responses and proliferation. Annotations enriched among down-regulated genes in kidney were fewer in number and of lower significance, reflecting changes in biosynthetic processes, while the annotations corresponding to lymph node down-regulated genes included cell adhesion, control of proliferation by follistatins as well as some biosynthetic processes ([Table 3](#tbl0015){ref-type="table"}).

It is clear from the observed pathology of MCF that non-lymphoid organs experience a significant influx of lymphoid cells (including virus-infected cells) which contribute to lesion development. Thus the annotation enrichment for kidney is likely to reflect the transcriptional activity of activated lymphocytes that are responsible for the observed pathology of MCF. Lymph node hyperplasia is a known element of MCF pathology ([@bib0005; @bib0055; @bib0110]) and this is reflected in the annotation enriched in this tissue. Thus the tissue-specific differences in enriched annotation in response to MCF may reflect both disease-specific changes in gene expression and changing cell populations in the different tissues.

3.5. Pathway analysis of differentially expressed genes {#sec0065}
-------------------------------------------------------

Differentially regulated pathways were also investigated using Ingenuity Pathway Analysis. Briefly, *p*~*f*~ and FC values associated with the entire dataset of lymph node and kidney were uploaded to the IPA software for global analysis. Use of the entire dataset allowed those genes with small but significant changes in mean expression to contribute to the identification of significantly altered gene groups and pathways. It also allows the background of genes that did not change in expression to contribute to the evaluation of potentially significant pathways. The main findings of this analysis are summarised in [Table 4](#tbl0020){ref-type="table"}.

This analysis also highlights differences between kidney and lymph node gene expression patterns, especially in the networks, disorders and pathways that were identified as having significant scores or *p*-values. The most significant networks/disorders identified included those associated with cancer and cell proliferation in the lymph node; and antigen presentation and inflammatory responses in the kidney ([Table 4](#tbl0020){ref-type="table"}). Indeed, across a range of analyses performed with the IPA database ([Table 4](#tbl0020){ref-type="table"}), there appears to be a clear difference in the balance of transcriptional activity induced by MCF. The lymph node sees changes in functions associated with cell proliferation and growth regulation, while changes in the kidney relate largely to increased immunological activity as well as proliferation. Significant up-regulation of pathways relating to immune function is seen only in the kidney (antigen presentation; CD28 signalling; iCOS--iCOSL signalling; Natural Killer cell signalling), identifying activated T lymphocytes and NK cells as likely effectors of tissue damage in MCF ([Table 4](#tbl0020){ref-type="table"}). Thus the observed transcriptional changes in the kidney appear to reflect an increase in the expression of activated lymphocyte phenotypes, while those in the lymph node indicate strong proliferative activity, potentially among resident lymphocytes.

4. Discussion {#sec0070}
=============

In this study, gene expression changes induced by AlHV-1 infection of a natural MCF-susceptible host (cattle) were analysed using microarrays carrying probes for approximately 23,000 bovine transcripts. Individual microarrays were used to interrogate RNA samples from lymph node and kidney of multiple cattle. Kidney was chosen as a non-lymphoid tissue in which MCF induces substantial lymphoid infiltration, forming visible lesions ([@bib0165]), while the inclusion of lymph node tissue in the analysis was intended to allow local changes in immune effector functions to be distinguished from more general mitogenic changes that are a consequence of lymphoproliferation. The use of both lymphoid and non-lymphoid tissues, therefore, may also aid the interpretation of the data compared to the use of either individual tissue. The observation that more genes were found with significantly altered expression due to MCF in the kidney compared to lymph node supports the view that the kidney is an appropriate tissue in which to define the effects of MCF in cattle.

Initial analysis of the microarray results identified 35 genes whose mean expression was significantly increased in both MCF-affected tissues ([Table 2](#tbl0010){ref-type="table"}A). These genes encode a range of proteins, including immunological effector molecules and chemokines. Closer examination of these highly expressed genes may provide clues to MCF pathogenesis.

One group of up-regulated genes encoded cytotoxic effector molecules. These included granulysin, granzyme H and perforin (GNLY, GZMH and PRF1; [Table 2](#tbl0010){ref-type="table"}), while granzyme B (GZMB) was found to be up-regulated in kidney by microarray analysis and in both tissues by qRT-PCR ([supplementary Table S1](#sec0080){ref-type="sec"}, [Fig. 1](#fig0005){ref-type="fig"}). This group included the most highly up-regulated genes in both tissues, underlining their significance in the generation of MCF pathology.

Chemokine ligands formed another group of up-regulated genes. CCL3, CCL4, CCL5 and CXCL11 were up-regulated in both tissues while CCL8, CCL19 and CXCL10 were up-regulated in kidney. These are all pro-inflammatory chemokines that function by recruiting and activating T cells and other lymphocytes. In particular, CXCL10 and CXCL11 bind the receptor CXCR3 on activated T cells to recruit them to peripheral sites. These chemokines and their receptor are associated with T cell trafficking in a range of inflammatory conditions and autoimmune diseases ([@bib0090]). They may therefore play a role in the T cell infiltration that appears to be a central feature of MCF pathogenesis. A CXCR3 antagonist compound has been shown to inhibit chemotaxis and attenuate disease in a range of autoimmune models ([@bib0120]). MCF can be viewed as a disease exhibiting similarities to autoimmune pathogenesis that makes the CXCR3 receptor and its ligands interesting targets for future research and potential therapies.

Several of the genes in [Table 2](#tbl0010){ref-type="table"}A are inducible by IFNγ (*e.g.* CCL3, CCL4, CCL5, CXCL11, IDO, UBD), suggesting that this may be a common factor underlying the pathogenesis of MCF. IFNγ itself was up-regulated by over 3-fold in the tissues analysed here ([Table 2](#tbl0010){ref-type="table"}), supporting the view that it may be responsible for many of the expression changes observed. Indeed, aberrant expression of IFNγ has been associated with inflammatory and autoimmune diseases ([@bib0180]).

A previous microarray analysis of gene expression in MCF-affected lymph node from OvHV-2 infected cattle ([@bib0135]) showed that IL-2 expression was reduced in MCF-affected lymph node and suggested this might be a key to understanding MCF pathogenesis. This observation was confirmed by qPCR studies in AlHV-1 infected rabbits ([@bib0080]), that also detected up-regulation of IFNγ, perforin and IL-10, suggesting that the pathology of MCF was similar in rabbits infected with either of the major MCF viruses. The data presented here in AlHV-1-infected cattle confirmed the increased expression of pro-inflammatory cytokines and cytotoxic effectors in MCF ([Table 2](#tbl0010){ref-type="table"}), but provided no evidence for changes in expression of IL-2 or IL-10.

This could reflect a genuine difference in AlHV-1-infected cattle compared to OvHV-2-infected cattle, or MCF-affected rabbits. Alternatively, the expression differences observed may reflect the challenge system used in this work, since MCF induced by intranasal challenge has a longer incubation time than intravenous challenge ([@bib0095]) and the animals used here were euthanised at a relatively early clinical stage due to welfare requirements. Thus the load of infected cells in these tissues may have been lower than that in tissues used in previous work. Currently there is no simple, robust way of detecting and analysing virus-infected cells in the tissues of MCF-affected animals. Recent work using a recombinant MCF virus expressing luciferase illustrates one approach with the potential to address this issue in experimental systems ([@bib0075]). In addition, we have recently identified a novel gene in AlHV-1 and detected its mRNA in MCF lesions by RT-PCR and *in situ* hybridisation (G.C. Russell et al., unpublished data). This may be a useful tool for the analysis of infected cell frequencies in the tissues.

Gene ontology and pathway analysis ([Tables 3 and 4](#tbl0015 tbl0020){ref-type="table"}) suggested that immunological and inflammatory processes were increased in kidney compared with increased cell proliferation and trafficking in the lymph node. Non-reactive lymph node is likely to contain transcripts related to normal immunological processes, while kidney is not, so that transcription from lymphocytes recruited to the kidney as part of MCF pathogenesis is likely to make a greater impact on the pattern of gene expression than in the lymph node. However, the increased expression of cytotoxic effector genes and chemokine genes in the lymph node demonstrates that immunological dysregulation occurs in this tissue too, reflected in the observed lymph node pathology. This is in accord with reports that cytotoxic CD8 T lymphocytes infiltrate and proliferate in MCF lesions of bison and rabbits ([@bib0080; @bib0150]) and that many of these cells are likely to be infected ([@bib0075; @bib0080]).

The activities of the gene products over-expressed in both analysed tissues of the MCF-affected animals suggest that constitutive expression of inflammatory genes may contribute to the pathology of MCF ([Table 2](#tbl0010){ref-type="table"}) with overexpression of IFNγ playing an important role. Thus, virus-infected lymphocytes, disseminated *via* the circulation to multiple organs, may act through expression of IFNγ-induced CXC and CC cytokines to recruit activated cytotoxic T cells to peripheral sites. We can speculate that the expression of high levels of cytotoxic effector molecules by virus-infected and/or uninfected cells in MCF-affected tissues generates a non-specific T cell cytotoxicity that leads to tissue damage.

Interestingly, infected large granular lymphocyte (LGL) lines that can be established from tissues of MCF-affected animals have non-MHC-restricted cytotoxic activity, are known to express pro-inflammatory cytokines and have constitutively active *Lck* and *Fyn* kinase pathways ([@bib0010; @bib0175; @bib0195]). These cell lines have been suggested to represent the infected cells *in vivo*. The microarray data presented here adds further evidence for a connection between the phenotype of LGL lines and MCF pathogenesis. Strong evidence of cytotoxic activity, activated T cell signalling and the up-regulation of IFNγ expression are seen both in the LGLs and in MCF-affected cattle tissues ([@bib0175; @bib0195]).

In conclusion, this study of AlHV-1 induced MCF in cattle, a naturally susceptible host, confirms the results of previous studies of MCF in rabbits or OvHV-2-infected cattle with respect to a possible role for increased cytotoxicity, and for IFNγ-stimulated immune and inflammatory responses, but differs with respect to IL-2 depression. This requires further analysis, including assays to confirm that changes in mRNA expression are reflected at the level of protein expression and activity. The expression of up-regulated genes, such as GNLY, CXCL11, UBD or IFNγ, in MCF-virus-infected cells also warrants further study in order to clarify their role in pathogenesis---whether they act directly to initiate tissue damage *via* cytotoxic activity or indirectly by recruiting and activating cytotoxic T cells at lesion sites.

Appendix A. Supplementary data {#sec0080}
==============================

The following is the supplementary data to this article:Supplementary Table S1Known genes with at least 2-fold change between MCF-affected and control tissues in either kidney or lymph node. Fold-change in gene expression (FC) and *p*-values adjusted for false discovery rate (*p*~*f*~) are listed for kidney (K) and lymph node (LN) samples, in order of greatest fold-change in either tissue. Where FC and *p*~*f*~ data are not present, the corresponding gene expression changes were not found to be significant at the 99% level.

We are grateful to the staff of the Moredun Research Institute Bioservices Division for excellent support during the animal studies described in this work. Microarray hybridisation and data extraction were performed by the ARK-Genomics Centre for Comparative and Functional Genomics ([www.ARK-genomics.org](http://www.ark-genomics.org/)). This work was funded by the Scottish Government\'s Rural and Environment Science and Analytical Services Division and by the UK Biotechnology and Biological Sciences Research Council (BB/H008950).

Supplementary data associated with this article can be found, in the online version, at [http://dx.doi.org/10.1016/j.virusres.2012.08.011](10.1016/j.virusres.2012.08.011).

![Gene expression fold-change values derived from qPCR data. The changes in expression of four genes: glucose-6-phosphate isomerase (GPI); granulysin (GNLY); granzyme B (GZMB); and granzyme H (GZMH) in MCF-affected tissues were normalised to ribosomal protein S9 (RPS9) and plotted with respect to equivalent tissues from control animals. Results of kidney transcript assays are in the light columns while results of lymph node assays are in the dark columns.](gr1){#fig0005}

###### 

Primer and probe sequences used for quantitative PCR.

  Gene symbol   Oligonucleotide sequence (5′--3′)     Accession number of cDNA
  ------------- ------------------------------------- -------------------------------------
  RPS9-F        GCCTCGACCAAGAGCTGAAG                  [DT860044](ncbi-n:DT860044)
  RPS9-R        GGGCAGCCTTTCGGATCT                    
  RPS9-P        FAM-TGATCGGCGAGTATGGGCTCCG-TAMRA      
                                                      
  G6PI-F        CATTGCCTCCAAGACCTTCAC                 [NM_001040471](ncbi-n:NM_001040471)
  G6PI-R        GGCCGACAGGAGAAACC                     
  G6PI-P        TET-ACCCAGGAGACCATCACGAACGCA-TAMRA    
                                                      
  GNLY-F        TGGGCTGTCCTGCTCATCA                   [NM_001075143](ncbi-n:NM_001075143)
  GNLY-R        TCAGGAGTCAGACCGGAAAAA                 
  GNLY-P        TET-CTCGGTGCTCCTGGTTGCCCC-TAMRA       
                                                      
  GRNZH-F       GCTGGGAGAGGAGATCATTGG                 [XM_002696688](ncbi-n:XM_002696688)
  GRNZH-R       CAGAAACTGAACGAAAGCCATGT               
  GRNZH-P       TET-CCAAGCCCCACTCCCGCCC-TAMRA         
                                                      
  GRNZB-F       GTAGGTGCGGTGGGTTCCT                   [XM_002696646](ncbi-n:XM_002696646)
  GRNZB-R       TTGATTGAGCTTCCGTTGCA                  
  GRNZB-P       TET-TCGACAGGACTTCGTGCTGACAGCC-TAMRA   

###### 

Known genes with at least 2-fold change between MCF-affected and control tissues.

  Gene symbol[a](#tblfn0005){ref-type="table-fn"}                                    Gene title[b](#tblfn0010){ref-type="table-fn"}          K (FC)[c](#tblfn0015){ref-type="table-fn"}   K (*p*~*f*~)[d](#tblfn0020){ref-type="table-fn"}   LN (FC)   LN (*p*~*f*~)
  ---------------------------------------------------------------------------------- ------------------------------------------------------- -------------------------------------------- -------------------------------------------------- --------- ---------------
  **(A) Genes significantly up-regulated in both tissues of MCF-affected animals**                                                                                                                                                                     
  GNLY                                                                               Granulysin (mean)[e](#tblfn0025){ref-type="table-fn"}   8.9                                          0.0009                                             16.5      0.0002
  GZMH                                                                               Granzyme H                                              10.2                                         \<0.0001                                           15.1      \<0.0001
  CXCL11                                                                             Chemokine (C--X--C motif) ligand 11                     14.3                                         0.0001                                             8.4       0.0009
  UBD                                                                                Ubiquitin D (mean)                                      13.8                                         \<0.0001                                           3.2       0.0080
  CCL4                                                                               Chemokine (C--C motif) ligand 4                         8.8                                          \<0.0001                                           4.8       0.0002
  CD8A                                                                               CD8a molecule                                           7.2                                          \<0.0001                                           2.4       0.0007
  CCL5                                                                               Chemokine (C--C motif) ligand 5                         5.9                                          \<0.0001                                           3.1       0.0002
  PLAC8                                                                              Placenta-specific 8 (mean)                              5.8                                          0.0001                                             5.6       0.0014
  IDO1                                                                               Indoleamine 2,3-dioxygenase 1 (mean)                    5.5                                          0.0001                                             4.9       0.0004
  CCL3                                                                               Chemokine (C--C motif) ligand 3 (mean)                  4.9                                          \<0.0001                                           3.0       0.0008
  OASL                                                                               2′--5′-oligoadenylate synthetase-like                   2.2                                          0.0058                                             3.8       0.0003
  HOPX                                                                               HOP homeobox                                            3.7                                          \<0.0001                                           3.1       0.0004
  FCGR3A                                                                             Low affinity Fc receptor IIIa, IgG (CD16a)              3.5                                          \<0.0001                                           2.2       0.0011
  WARS                                                                               Tryptophanyl-tRNA synthetase (mean)                     3.5                                          \<0.0001                                           2.3       0.0009
  IFNG                                                                               Interferon, gamma                                       3.0                                          0.0024                                             3.3       0.0016
  RRM2                                                                               Ribonucleotide reductase M2 polypeptide                 3.2                                          0.0010                                             2.6       0.0048
  PRF1                                                                               Perforin 1 (pore forming protein)                       3.1                                          \<0.0001                                           2.4       0.0006
  CKS2                                                                               CDC28 protein kinase regulatory subunit 2               2.5                                          0.0015                                             3.1       0.0005
  SH2D1A                                                                             SH2 domain protein 1A                                   3.0                                          \<0.0001                                           2.7       0.0004
  MTHFD2                                                                             Methylenetetrahydrofolate dehydrogenase 2               2.8                                          0.0003                                             2.3       0.0006
  LMNB1                                                                              Lamin B1                                                2.3                                          0.0047                                             2.8       0.0010
  CCR5                                                                               Chemokine (C--C motif) receptor 5                       2.5                                          0.0001                                             2.5       0.0005
  PPA1                                                                               Pyrophosphatase (inorganic) 1                           2.5                                          0.0002                                             2.4       0.0006
  NCAPG                                                                              Non-SMC condensin I complex, subunit G                  2.5                                          0.0006                                             2.1       0.0029
  ISG20                                                                              Interferon stimulated exonuclease gene 20 kDa           2.5                                          0.0012                                             2.4       0.0016
  CDCA8                                                                              Cell division cycle associated 8                        2.5                                          0.0005                                             2.2       0.0017
  NUSAP1                                                                             Nucleolar and spindle associated protein 1              2.4                                          0.0021                                             2.1       0.0057
  CD96                                                                               CD96 molecule                                           2.4                                          0.0003                                             2.4       0.0006
  TOP2A                                                                              Topoisomerase (DNA) II alpha 170 kDa (mean)             2.4                                          0.0077                                             2.1       0.0090
  UBE2C                                                                              Ubiquitin-conjugating enzyme E2 C                       2.3                                          0.0004                                             2.2       0.0009
  CCNB2                                                                              Cyclin B2                                               2.1                                          0.0051                                             2.1       0.0032
  CRELD2                                                                             Cysteine-rich with EGF-like domains 2                   2.0                                          0.0070                                             2.1       0.0048

  Gene symbol                                                                          Gene name                            K (1/FC)[f](#tblfn0030){ref-type="table-fn"}   K (*p*~*f*~)   LN (1/FC)   LN (*p*~*f*~)
  ------------------------------------------------------------------------------------ ------------------------------------ ---------------------------------------------- -------------- ----------- ---------------
  **(B) Genes significantly down-regulated in both tissues of MCF-affected animals**                                                                                                                  
  CIRBP                                                                                Cold inducible RNA binding protein   3.3                                            \<0.0001       3.3         0.0002
  STAG3                                                                                Stromal antigen 3 (mean)             2.5                                            0.0001         2.5         0.0004
  RBM3                                                                                 RNA binding motif protein 3 (mean)   2.0                                            0.0008         2.5         0.0002

Gene identities for probesets from the Affymetrix GeneChip Bovine Genome Arrays were obtained from the NetAffx™ Analysis Center ([www.affymetrix.com/analysis/index.affx](http://www.affymetrix.com/analysis/index.affx)) or were assigned following sequence-based database searching.

Genes are ordered on the basis of their maximal expression change in either tissue.

Fold-change in gene expression (FC) in MCF compared to control tissue, and *p*-values adjusted for false discovery rate (*p*~*f*~) are listed for kidney (K) and lymph node (LN) samples.

False discovery rate adjusted *p*-values (*p*~*f*~) are expressed with 4-decimal precision.

Where multiple probesets representing the same gene were significantly altered in expression, the FC value given is the mean, indicated in the gene name column, while the *p*~*f*~ value shown is the highest of the probesets analysed.

Degree of down-regulation is expressed as the inverse of the fold-change (1/FC).

###### 

DAVID software analysis.

  Annotation type[a](#tblfn0035){ref-type="table-fn"}                          Kidney                                             Score [b](#tblfn0040){ref-type="table-fn"}   *p*-Value [c](#tblfn0045){ref-type="table-fn"}   Lymph node                      Score   *p*-Value
  ---------------------------------------------------------------------------- -------------------------------------------------- -------------------------------------------- ------------------------------------------------ ------------------------------- ------- -----------
  Up-regulated annotation clusters                                             Antigen processing and presentation                6.0                                                                                           Cell division                   6.2     
                                                                               Inflammatory response                              5.8                                                                                           Mitosis, cell cycle             2.8     
                                                                               Regulation of immune response                      5.3                                                                                           Chemokines and receptors        2.4     
                                                                               Regulation of lymphocyte mediated immunity         3.6                                                                                           Autoimmune reaction             2.4     
                                                                               Regulation of lymphocyte activation                3.5                                                                                           Meiosis                         2.0     
                                                                                                                                                                                                                                                                        
  Up-regulated KEGG pathways                                                   Antigen processing and presentation                                                             \<0.0001                                         Meiosis                                 0.0001
                                                                               Allograft rejection                                                                             \<0.0001                                         Graft-*versus*-host disease             0.0013
                                                                               Graft-*versus*-host disease                                                                     \<0.0001                                         Cell cycle                              0.0018
                                                                               Viral myocarditis                                                                               \<0.0001                                         Allograft rejection                     0.0018
                                                                               Cell adhesion molecules                                                                         \<0.0001                                         Cytokine-receptor interaction           0.0020
                                                                                                                                                                                                                                                                        
  Down-regulated annotation clusters                                           Short-chain dehydrogenase/reductase                2.0                                                                                           Cell adhesion                   3.0     
                                                                                                                                                                                                                                Follistatin-like proteins       2.5     
                                                                                                                                                                                                                                Protein phosphatase binding     2.1     
                                                                                                                                                                                                                                Embryonic development           1.5     
                                                                                                                                                                                                                                Membrane organisation           1.4     
                                                                                                                                                                                                                                                                        
  Down-regulated KEGG pathways/GO terms [d](#tblfn0050){ref-type="table-fn"}   GO:0055114 oxidation-reduction                                                                  \<0.0001                                         Cell adhesion molecules                 0.001
                                                                               GO:0045833 regulation of lipid metabolic process                                                0.0047                                           Cardiomyopathy                          0.005
                                                                               GO:0005932 microtubule basal body                                                               0.0068                                                                                   

Enriched annotation terms among genes with altered regulation (based on genes with *p*~*f*~ \< 0.01 and FC \> 2 from the microarray analysis). In each annotation type the top five entries with score \> 1 or *p* \< 0.01 are shown.

The significance of enrichment was measured by the *score*, the geometric mean (−log) of the *p*~*f*~-values of the contributing genes, or by the *p*-value.

*p*-values were derived by a modified Fisher\'s exact test.

No significant enrichment of genes in KEGG pathways was seen among down-regulated genes in the kidney, so the most significantly enriched gene ontology (GO) terms (*p* \< 0.01) are given for this gene set.

###### 

Pathway analysis (IPA, based on all probesets).

  Classification            Kidney                                                                                                                  Score[a](#tblfn0055){ref-type="table-fn"}   *p*[a](#tblfn0055){ref-type="table-fn"}   Molecules[b](#tblfn0060){ref-type="table-fn"}   Lymph node                                                                               Score   *p*        Molecules
  ------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ----------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------------------------- ------- ---------- -----------
  Top networks              Cellular assembly and organisation; genetic disorder; ophthalmic disease.                                               37                                                                                                                                    RNA post transcriptional modification; protein synthesis; small molecule biochemistry.   37                 
                            Antigen presentation; inflammatory response; genetic disorder.                                                          35                                                                                                                                    Cell cycle; developmental disorder; genetic disorder.                                    37                 
                            DNA replication, recombination and repair; cellular assembly and organisation; cell--cell signalling and interaction.   35                                                                                                                                    Cancer; cell cycle; cellular growth and proliferation.                                   33                 
                            Amino acid metabolism; protein synthesis; small molecule biochemistry.                                                  31                                                                                                                                    Cellular movement; nervous system development and function; cell morphology.             32                 
                            Cellular development; haematological system development and function; haematopoiesis.                                   31                                                                                                                                    Protein trafficking, RNA post-transcriptional modification, molecular transport.         32                 
                                                                                                                                                                                                                                                                                                                                                                                                      
  Top diseases/disorders    Inflammatory response.                                                                                                                                              0.0006                                    217                                             Cancer.                                                                                          0.021      659
                            Immunological disease.                                                                                                                                              0.0006                                    270                                             Genetic disorder.                                                                                0.020      247
                            Inflammatory disease.                                                                                                                                               0.0006                                    292                                             Respiratory disease.                                                                             0.001      113
                            connective tissue disorders.                                                                                                                                        0.0001                                    200                                             Gastrointestinal disease.                                                                        0.020      239
                            skeletal and muscular disorders.                                                                                                                                    0.0002                                    275                                             Reproductive system disease.                                                                     0.020      367
                                                                                                                                                                                                                                                                                                                                                                                                      
  Top molecular functions   Cellular growth and proliferation.                                                                                                                                  0.0005                                    254                                             Cell cycle.                                                                                      0.021      291
                            Cellular development.                                                                                                                                               0.0006                                    215                                             Cellular assembly and organisation.                                                              0.014      79
                            Cellular function and maintenance.                                                                                                                                  0.0005                                    136                                             DNA replication, recombination and repair.                                                       0.019      164
                            Cell death.                                                                                                                                                         0.0004                                    292                                             Cellular movement.                                                                               0.020      191
                            Cell--cell signalling and interaction.                                                                                                                              0.0005                                    207                                             Antigen presentation.                                                                            0.014      33
                                                                                                                                                                                                                                                                                                                                                                                                      
  Top canonical pathways    Antigen presentation.                                                                                                                                               \<0.0001                                  16/43                                           Mitochondrial dysfunction.                                                                       \<0.0001   42/169
                            CD28 signalling in Th cells.                                                                                                                                        \<0.0001                                  33/135                                          Protein ubiquitination pathway.                                                                  \<0.0001   66/274
                            iCOS--iCOSL signalling in T helper cells.                                                                                                                           \<0.0001                                  27/125                                          Ubiquinone biosynthesis.                                                                         \<0.0001   26/119
                            Natural Killer cell signalling.                                                                                                                                     \<0.0001                                  25/116                                          Mitotic roles of polo-like kinase.                                                               \<0.0001   21/63
                            Systemic Lupus Erythematosus signalling.                                                                                                                            \<0.0001                                  25/125                                          Cell cycle control of chromosomal replication.                                                   \<0.0001   14/31

The *score* (integer; negative log of respective IPA *p*-value) or maximum *p*-value assigned by the IPA software for each classification is given. IPA uses a right tailed Fisher\'s exact test to calculate *p*-values.

The number of molecules with significantly altered expression assigned to each classification from the submitted gene lists or the number of genes/total number of molecules in pathway.

[^1]: Present address: Instituto de Ganaderia de Montaña (CSIC-ULE), 24346 Grulleros (Leon), Spain.
